A Phase 1, Open-Label Extension Groups Study in Subjects Having Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease
Latest Information Update: 05 Sep 2025
At a glance
- Drugs Saroglitazar (Primary)
- Indications Liver cirrhosis; Liver disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Zydus Cadila
Most Recent Events
- 15 Aug 2025 Planned End Date changed from 30 Jun 2024 to 31 Dec 2025.
- 15 Aug 2025 Planned primary completion date changed from 30 Jun 2024 to 31 Dec 2025.
- 04 Mar 2025 Planned number of patients changed from 24 to 30.